Xiamen Amoytop Biotech Hits Day High with Strong 4.29% Intraday Surge

Xiamen Amoytop Biotech Co. has experienced a notable increase of 4.29% on June 8, 2026, reaching an intraday high of CNY 57.35. This performance stands in contrast to the China Shanghai Composite, which declined by 1.7% on the same day. Over the past week, Xiamen Amoytop has shown a 2.41% gain, while the broader market has faced a 2.43% drop. Despite a challenging year, where the stock has underperformed with a return of -22.12%, the company has consistently reported positive results for the last 18 consecutive quarters. Key financial metrics indicate a robust operational performance, with net sales reaching a record CNY 1,216.02 million and an operating profit of CNY 472.2 million. The company boasts a return on equity of 34.50% and a price-to-book ratio of 12.11, reflecting a fair valuation in the current market landscape. With a market capitalization of CNY 23,330 million, Xiamen Amoytop continues to navigate the pharmaceuticals and biotechnology sector, showcasing resilience amid broader market fluctuations.